Jean Claude Marcourt was born in Awans, on October 16, 1956. He is married, and has two children. He graduated in law from the University of Liège (1974-1979) and later became a lawyer at the Bar of Liège (on leave since 1992). He was first cabinet chief for many ministers between 1992 and 2004, and became minister in 2004. Since 2014, he has been Minister of Economy, Industry, Innovation and Digital Affairs, Vice President of the Walloon Government. Minister of Higher Education, Research and Media, Vice-President of the Government of the Wallonia-Brussels Federation
Doctorate in molecular genetics at UCL
Post-Doc in Montreal in human genetics at the Charles Bruneau Institute, specializing in pediatric cancers
19 years in biotech companies (ABI, Life Technologies, Thermo Fisher Scientific and Qiagen)
since October 2016 at OncoDNA
CEO, 42, is a pharmacist and Qualified Person. He completed his education with an MBA from IAG-UCL and a post-graduate teaching diploma. Before setting up OncoDNA end of 2012, he worked in Quality Assistance, a service provider for the pharmaceutical industry, accredited ISO17025, certified GLP and inspected by the FDA. Over 6 years he held different posts in the company and their variety meant he was able to develop expertise in business development, organisation and management.
In 2004, with the help of ULB and IPG, he set up DNAVision, a company specialised in the development and validation of innovative DNA tests for the pharmaceutical and food industries. In two years, DNAVision became the first company in Europe to provide the pharmaceutical industry with ISO17025 accredited pharmacogenetic tests. DNAVision was certified GLP and GMP and also CLIA certified for analyses for the US.
obtained a PhD in sciences at the Laboratory of Genetics, University of Ghent (Belgium). During his 10 years academic career, he gained broad experience in plant pathogen interactions, protein chemistry, molecular biology and cell biology. He worked for about 7 years within the biotech industry at Plant genetic Systems (now Bayer Crop Science) where he was involved in regulatory affairs and biotech product quality assurance. During this period, he gained real-life experience with global registration processes, accreditation, product quality control/assurance and business relationships. Since 2003, he works at the Scientific Institute of Public Health (Brussels, Belgium) where he supported the establishment of the National Reference Laboratory on GMO detection till 2009. He worked for 3 years as a contract agent at the ‘Institute of Health and Consumer Protection’ at the Joint Research Centre of the European Commission where he coordinated policy-support research in molecular detection.
Since 2013, he heads the Cancer Centre at the Scientific Institute of Public Health, a unit dedicated at the monitoring and evaluation of the activities in cancer control in Belgium. Current key activities of the Cancer Centre focus on the introduction of Next-Generation-Sequencing (NGS) in routine diagnostics in Belgium, on models to support the socio-professional reintegration of cancer patients, on developing a long-term strategy for cancer in Belgium, on screening and early detection (expert focus on cervical cancer) and on integrating patients, citizens and general practitioners in the policy support activities of the Cancer Centre.
In the joint action CanCon, the Cancer Centre has as principle task to coordinate the production of the final deliverable, a guide on quality improvement in cancer care. Also, we are responsible on developing a position paper on ‘Public Health Genomics in cancer’. The Cancer Centre is also partner in the new joint action on ‘Rare Cancers’.
Dr Sònia Pernas completed her University degree in Medicine and Surgery (MD) at University of Barcelona ( Spain) in 1999. After successfully completing her Medical Oncology internship and residency at Hospital de la Santa Creu i Sant Pau in Barcelona in 2004, Sònia joined the Breast Cancer Unit at Catalan Institute of Oncology, where she has been working as attending physician with full time dedication during the last 12 years. Since 2013, she is the head of the Breast Cancer Unit of this institution. She has extensive experience in clinical research, being involved in many phase 1 to 3 Breast Cancer clinical trials. Her field of research interest has focused on HER2-positive Breast Cancer. This interest is reflected in some of her publications and in the topic of her PhD thesis. Other fields of interest include biomarkers of response/resistance to therapy in breast cancer and identifying novel actionable target genes in order to develop rational combination of therapies. She is member of Executive Committee of SOLTI , since February 2015 and together with Dr Eva Ciruelos, she is the global Co-PI of the AGATA study, the first multi-institutional molecular screening program implemented in patients with advanced breast cancer in Spain.
received his oncology training at the University Hospital of Zurich, Switzerland. He completed a research fellowship at Institut Jules Bordet, during which he commenced a PhD at the Université Libre de Bruxelles, Brussels, Belgium, focusing on PI3K pathway in breast cancer. Currently he works at Breast International Group as Associate Medical Director, designing and setting-up clinical trials in the field of breast cancer with emphasis on molecularly targeted agents. He is part of the core scientific team working for the AURORA initiative of molecular profiling for patients with advance breast cancer, sponsored by BIG’.
After a Phd in Genomics, Molecular Biology, Genetics at ULB, I worked during several years in different biotech companies (Life Technologies, DNA Vision, Biovallee). Since february 2013, I’m CTO (Chief Technological Officer) at OncoDNA. I'm responsible for establishing the OncoDNA’s technical vision and leading all aspects of the company’s technology development.